AACR 2022: Tollys releases new preclinical data demonstrating lifelong potent anti-tumor immunity of
Specific TLR3-agonist TL-532 induces lifelong anti-tumor auto-vaccinationData also showed cross-immunity against unrelated cancersThese results confirm two new properties for TL-532, which showed proof-of-concept of inducing tumor cell death by apoptosis and reversing resistance to immune checkpoint inhibitors in pr...
Source: pharmiweb.com